|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 面向21世纪的卒中新定义:美国心脏病学会和美国卒中学会声明显示文摘尽管脑血管病有着全球性影响且对其病理生理学的认识有了很多进步,但是'卒中'这一术语在临床实践、临床研究或公共卫生评估中的定义却不一致。传统的定义依据于临床,却没有考虑到科学技术的进步。美国心脏协会(AHA)和美国卒中协会(ASA)卒中分会组织了写作小组,为21世纪卒中新定义撰写专家共识性声明。中枢神经系统(CNS)梗死,指由缺血所导致的脑、脊髓或视网膜的细胞死亡,是基于持续性损害的神经病理学、神经影像学和(或)临床证据。CNS梗死表现为一个临床谱:缺血性卒中特指伴有明显症状的CNS梗死,而静息性梗死根据定义指未引起已知的症状的梗死。卒中也还包括脑出血和蛛网膜下腔出血。新定义的卒中结合了临床和组织学标准,可被用于实践、研究和公共卫生评估。 | 俞羚 董荃 宋叶平 江静雯 李卉 刘亮贤 苏爱萍 李焰生 Sacco RL Kasner SE Broderick JP Caplan LR Connors JJ Culebras A Elkind MS George MG Hamdan AD Higashida RT Hoh BL Janis LS Kase CS Kleindorfer DO Lee JM Moseley ME Peterson ED Turan TN Valderrama AL Vinters HV | 2013 | 神经病学与神经康复学杂志2013，10，2： | 188 |
| 2 | Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease显示文摘Inflammatory bowel disease (IBD), in particular Crohn's disease refractory to conventional therapy, fistulizing Crohn's disease and chronic active ulcerative colitis, generally respond well to anti-tumor necrosis factor (TNF) therapy. However, serious side effects do occur, necessitating careful monitoring of therapy. Potential side effects of anti-TNF therapy include opportunistic infections, which show a higher incidence when concomitant immunosuppression is used. Furthermore, antibody formation against anti-TNF is associated with decreased efficacy and an increased frequency of infusion reactions. The hypothesis of a slightly increased risk of lymphomas in IBD patients treated with anti TNF-therapy is debatable, since most studies lack the specific design to properly address this issue. Alarmingly, the occurrence of hepatosplenic T-cell lymphomas coincides with combined immunosuppressive therapy. Despite the potential serious side effects, anti-TNF therapy is an effective and relatively safe treatment option for refractory IBD. Future research is needed to answer important questions, such as the long-term risk of malignancies, safety during pregnancy, when to discontinue and when to switch anti-TNF therapy, as well as to determine the balance between therapeutic and toxic effects. | Frank Hoentjen Ad A van Bodegraven | 2009 | World Journal of Gastroenterology2009，15，17： | 19 |
| 3 | Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres显示文摘BACKGROUND Mixed neuroendocrine non-neuroendocrine neoplasm(MiNEN)is a rare diagnosis,mainly encountered in the gastro-entero-pancreatic tract.There is limited knowledge of its epidemiology,prognosis and biology,and the best management for affected patients is still to be defined.AIM To investigate clinical-pathological characteristics,treatment modalities and survival outcomes of a retrospective cohort of patients with a diagnosis of MiNEN.METHODS Consecutive patients with a histologically proven diagnosis of MiNEN were identified at 5 European centres.Patient data were retrospectively collected from medical records.Pathological samples were reviewed to ascertain compliance with the 2017 World Health Organisation definition of MiNEN.Tumour responses to systemic treatment were assessed according to the Response Evaluation Criteria in Solid Tumours 1.1.Kaplan-Meier analysis was applied to estimate survival outcomes.Associations between clinical-pathological characteristics and survival outcomes were explored using Log-rank test for equality of survivors functions(univariate)and Cox-regression analysis(multivariable).RESULTS Sixty-nine consecutive patients identified;Median age at diagnosis:64 years.Males:63.8%.Localised disease(curable):53.6%.Commonest sites of origin:colon-rectum(43.5%)and oesophagus/oesophagogastric junction(15.9%).The neuroendocrine component was;predominant in 58.6%,poorly differentiated in 86.3%,and large cell in 81.25%,of cases analysed.Most distant metastases analysed(73.4%)were occupied only by a poorly differentiated neuroendocrine component.Ninety-four percent of patients with localised disease underwent curative surgery;53%also received perioperative treatment,most often in line with protocols for adenocarcinomas from the same sites of origin.Chemotherapy was offered to most patients(68.1%)with advanced disease,and followed protocols for pure neuroendocrine carcinomas or adenocarcinomas in equal proportion.In localised cases,median recurrence free survival(RFS);14.0 months(95%CI:9.2-24.4),and median overall survival(OS):28.6 months(95%CI:18.3-41.1).On univariate analysis,receipt of perioperative treatment(vs surgery alone)did not improve RFS(P=0.375),or OS(P=0.240).In advanced cases,median progression free survival(PFS);5.6 months(95%CI:4.4-7.4),and median OS;9.0 months(95%CI:5.2-13.4).On univariate analysis,receipt of palliative active treatment(vs best supportive care)prolonged PFS and OS(both,P<0.001).CONCLUSION MiNEN is most commonly driven by a poorly differentiated neuroendocrine component,and has poor prognosis.Advances in its biological understanding are needed to identify effective treatments and improve patient outcomes. | Melissa Frizziero Xin Wang Bipasha Chakrabarty Alexa Childs Tu V Luong Thomas Walter Mohid S Khan Meleri Morgan Adam Christian Mona Elshafie Tahir Shah Annamaria Minicozzi Wasat Mansoor Tim Meyer Angela Lamarca Richard A Hubner Juan W Valle Mairéad G McNamara | 2019 | World Journal of Gastroenterology2019，25，39： | 13 |
| 4 | Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial显示文摘 | Geert D’Haens Filip Baert Gert van Assche Philip Caenepeel Philippe Vergauwe Hans Tuynman Martine De Vos Sander van Deventer Larry Stitt Allan Donner Severine Vermeire Frank J Van De Mierop Jean-Charles R Coche Janneke van der Woude Thomas Ochsenkühn Ad A | 2008 | The Lancet2008，，9613： | 5 |
| 5 | Ethanol metabolism and its effects on the intestinal epithelial barrier显示文摘 | Elhaseen E Elamin Ad A Masclee Jan Dekker Daisy M Jonkers | 2013 | Nutr Rev2013，，7： | 3 |
| 6 | Indications for 5-aminosalicylate in inflammatory bowel disease:Is the body of evidence complete?显示文摘Mesalazine is a safe drug, although adverse events may be seen in a minority of patients. This applies also to pregnant women and children. The role of mesalazine in combination therapy to improve efficacy and con- comitant drug pharmacokinetics, or in chemoprevention against inflammatory bowel disease (IBD)-related co- lonic carcinoma has not yet been completely elucidated. Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dos- age to improve compliance. Therefore, due to its supe- rior safety profile and pharmacokinetic characteristics, mesalazine is preferable to sulphasalazine. This paper reviews the literature concerning mechanisms of action, indications and off-label use, pharmacokinetic properties and formulations, therapeutic efficacy, compliance, pae- diatric indications, chemoprevention, and safety issues and adverse event profile of mesalazine treatment versus sulphasalazine. It also highlights these controversies in order to clarify the potential benefits of mesalazines in IBD therapy and evidence for its use. | Ad A van Bodegraven Chris JJ Mulder | 2006 | World Journal of Gastroenterology2006，12，38： | 2 |
| 7 | Cardiac rehabilitation and survival in older coronary patients显示文摘 | Suaya J A Stason W B Ades P A | | 0，，01： | 2 |
| 8 | 冠状动脉内皮功能障碍患者胆固醇流出异常,高密度脂蛋白颗粒物浓度降低显示文摘冠状动脉内皮功能障碍(endothelial dysfunction,ED)是动脉粥样硬化早期标志,增加心血管事件发生风险。该研究假设胆固醇流出容量和高密度脂蛋白颗粒浓度(high-density lipoprotein particle concentration,HDL-PIMA)较高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)更能预测ED。 | 刘莉 叶鹏 Monette JS Hutchins PM Ronsein GE Wimberger J Irwin AD Tang C Sara JD Shao B Vaisar T Lerman A Heinecke JW | 2016 | 中华高血压杂志2016，24，6： | 2 |
| 9 | Reevaluation of bone marrow-derived cells as a source for hepatocyte regeneration显示文摘 | Cantz T Sharma AD Jochheim-Richter A | 2004 | Cell Transplant2004，13，6： | 1 |
| 10 | Secretion of vascular eudothelial growth factor in ovarian cancer显示文摘 | Hermonat PL Ravaggi A | 1999 | Eur J Gynaecol Oncol1999，20，3： | 1 |
| 11 | A prospective study on the clinical effect of surgical treatment of normal pressure hydrocephalus: the value of hydrodynamic evaluation 显示文摘 | Sorteberg A Eide PK Fremming AD | 2004 | Br J Neurosurg2004，18，2： | 1 |
| 12 | Flav onoid andchlorogenic acid levels inapple fruit: char acterisation of variation显示文摘 | AW AD M A JAGER A D van WESTING L M | 2000 | Scientia Horticulturae2000，83，34： | 1 |
| 13 | Gap-junction channelsdysfunction in deafness and hearing loss显示文摘 | Martínez AD Acua R Figueroa V | 2009 | Antioxid Redox Sig-nal2009，11，2： | 1 |
| 14 | Reduction in gram- positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin显示文摘 | Nardi G Di - Silvestre AD De - Monte A | 2001 | Eur J Emerg Med2001，8，3： | 1 |
| 15 | The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines 显示文摘 | Bell AD Roussin A Cartier R | 2011 | Can J Cardiol2011，27，： | 1 |
| 16 | Robot-assisted radical cystectomy with intracorporeal urinary diversion in patients with transitional cell carcinoma of the bladder显示文摘 | Jonsson MN Adding LC Hosseini A | 2011 | Eur Urol2011，60，5： | 1 |
| 17 | Retinal thickness in patients with mild cognitive impairment and Alzheimers' s disease 显示文摘 | Kesler A Vakhapova V Korczyn AD | 2011 | Clin Neurot Neurosurg2011，113，7： | 1 |
| 18 | A 24-month follow-up of flowable resin composite as an intermediate layer in non-carious cervical lesions显示文摘 | Reis A Loguercio AD | 2006 | Oper Dent2006，31，5： | 1 |
| 19 | Mechanisms of primary blast-induced traumatic brain injury: insights from shock-wave research 显示文摘 | Nakagawa A Manley GT Gean AD | 2011 | J Neurotrauma2011，28，6： | 1 |
| 20 | Com-parison of physical activity in male and female children :does maturation matter? 显示文摘 | Thompson A Baxter-Jones AD Mirwald RL | 2003 | Med Sci Sports Exerc2003，35，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员